CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
PBTC-056 PBTC A Phase I study of the ADAM-10 inhibitor, INCB7839 in children with recurrent/progressive high-grade gliomas to target microenvironmental neuroligin-3 Pediatric CIRB
PBTC-058 PBTC Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma Pediatric CIRB
PBTC-059 PBTC Phase 1 Trial of Autologous HER2-specific CAR T cells in Pediatric Patients with Refractory or Recurrent Ependymoma Pediatric CIRB
PBTC-060 PBTC A Pilot Study of Safety, Tolerability, and Immunological Effects of SurVaxM in Pediatric Patients with Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma Pediatric CIRB
PBTC-061 PBTC Phase 2 Trial of G207 + 5 Gy Radiation for Children with High-Grade Gliomas Pediatric CIRB
PBTC-N14 PBTC CSF Cell-free Tumor DNA (CSF cfDNA) Liquid Biopsies for Pediatric, Adolescent, and Young Adult Patients with Primary Brain Tumors Pediatric CIRB
PED-CITN-01 Pediatric CITN 3CI Study: Childhood Cancer Combination Immunotherapy. Phase 1b and Expansion Study of Nivolumab Combination Immunotherapy in Children, Adolescent and Young Adult (CAYA) Patients with Relapsed/Refractory Hypermutant Cancers Pediatric CIRB
PED-CITN-02 Pediatric CITN GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Sarcoma and Neuroblastoma to Increase Systemic Tumor Exposure Pediatric CIRB
PED-CITN-03 Pediatric CITN Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined with Dinutuximab in Children and Young Adults with Relapsed and Refractory Neuroblastoma or Relapsed Osteosarcoma Pediatric CIRB
PEPN1812 PEP-CTN A Phase 1 Trial of the CD123 X CD3 DART® Molecule Flotetuzumab (NSC#808294, IND#145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia Pediatric CIRB